E-mail ID : info@iamg.in |
Online Submission |
Click Here For Online Submission |
Instructions for authors |
Genetic Clinics |
Editorial board |
Get Our Newsletter |
Subscribe |
Send Your Feedback |
Feedback Form |
About Us |
IAMG |
Abstract
October to December 2019 | Vol. 12 | Issue 4 | 14 | |||
Molecular Diagnosis Aids in Specific Treatment of Rare Diseases | |||
Dhanya Lakshmi N | |||
Department of Medical Genetics, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India. | |||
Address for Correspondence Email: dhanya.lakshmi@manipal.edu | |||
Abstract Proteus syndrome is an overgrowth disorder caused by somatic mosaicism of the variant c.49G>A (p.Glu17Lys) in AKT1 gene. Miransertib, a small molecule that inhibits AKT1 has been tried in some cancers with the same variant in somatic cells. Noreuil et al. conducted a pharmacodynamic study of Miransertib in Proteus syndrome and concluded that a dose of 5mg/m2/day resulted in a 50% reduction in phosphorylated AKT in tissues of five out of six individuals. The authors demonstrated that 5mg/m2/day could be used as a starting dose of Miransertib for future drug efficacy trials in patients with Proteus syndrome. | |||
HTML Full Text | Download PDF |